RxDoctor Payments DataLook up a doctor →

Donna Graves, MD

Neurology · Charlotte, NCNPI 1578766192

Payments from drug & device makers

$1,791,676in general payments, 2019–2025

Across 272 payments — averaging $6587.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • F. Hoffmann-la Roche AG$886K
  • Novartis$681K
  • Roche Products Limited$107K
  • Genentech, Inc.$100K
  • EMD Serono, Inc.$7K
  • AstraZeneca$6K
  • plus $4K from 6 others
$2,221in research payments, 2019–2025

Across 8 payments — averaging $277.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi$2K

What the payments were for

  • Consulting fees$11,88270%
  • Travel & lodging$2,72916%
  • Food & beverage$2,11913%
  • Education$1311%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,791,676 in reported general payments places this provider in the 95th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$10,958
Medicare patients
64
Services billed
101

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab17$212,499
CopaxoneGlatiramer Acetate32$182,053
AubagioTeriflunomide13$114,205
VumerityDiroximel Fumarate12$100,982
PonvoryPonesimod11$94,578
Dalfampridine ErDalfampridine100$44,837
Dimethyl Fumarate15$32,798
FingolimodFingolimod Hcl12$11,118
Baclofen109$3,612
Gabapentin122$3,474
Pregabalin42$2,724
Modafinil43$2,423
Dantrolene Sodium20$1,298
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine38$1,142
Tizanidine Hcl43$1,123

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SanofiAubagio$3,223$114,20513 claims
BiogenVumerity$553$100,98212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 566 neurology providers in North Carolina.

Other neurology in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →